Drug Repositioning: A Union of Patient Interests, Pipeline Development and Innovation

March 29, 2011Biovista Articles

By Aris Persidis, PhD, President; Biovista, Inc., Charlottesville, Va. Tue, 03/29/2011 The tremendous pressures on pharmaceutical company pipelines are always in the news. Constant reorganizations and acquisitions of late-stage clinical candidates or of entire companies are seen as a major solution going forward. Yet, there is a new trend emerging. Existing drugs, whether in development, … Read More

Drug Repositioning podcast

March 10, 2011Biovista Articles, Multimedia

Drug repositioning as a viable business strategy. Biovista’s President A. Persidis interview to GEN’s editor in chief, John Sterling. “Prompted by the need to refurbish their pipelines at lower costs and to drive and sustain future profits, drug companies have turned to drug repositioning, or repurposing, as a means of drug rediscovery. The process of … Read More